Autopsy report · NCT04721535

A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2

“Termination of study due to sponsor's internal decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 4 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Daewoong Pharmaceutical Co. LTD.

Sponsor type

Industry

Conditions

Covid19; SARS-COV-2 Infection

Interventions

DWJ1248; Placebo

Participants

9

Sites

1

Countries

South Korea

Trials that died the same way

• Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
  “Sponsor decision to terminate study.” (91% match in meaning)
• Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
  “Sponsor decision to terminate the study” (89% match in meaning)
• Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
  “Study termination by the Sponsor” (88% match in meaning)
• The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
  “Business decision by sponsor to terminate the study” (87% match in meaning)
• A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
  “Study was terminated based on Sponsor decision” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.